Recombinant anti-HBsAg Fab blocks hepatitis B virus infection after orthotopic liver transplantation

Hepatobiliary and Pancreatic Diseases International

Volumn 6, Issue 4, 2007, Pages 370-375

  Pan, Tao ^a   Tang, Li ^a   Yuan, Jin ^a   Gong, Nian Qiao ^a   Wang, Da Wei ^a   Chen, Dun Xiu ^a   Guo, Hui ^a   Chen, Zhi Shui ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Hepatitis B virus; Liver transplantation; Monoclonal antibodies

Indexed keywords

HEPATITIS B ANTIBODY; LAMIVUDINE; LIPOSOME; PARVOVIRUS VECTOR; RECOMBINANT HEPATITIS B VACCINE; TISSUE CULTURE MEDIUM; TRYPAN BLUE;

ARTICLE; CELL STRAIN HEK293; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; GENE THERAPY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INFECTION RATE; LIVER TRANSPLANTATION; MORTALITY; ORTHOTOPIC TRANSPLANTATION; POSTOPERATIVE COMPLICATION; REINFECTION; STATISTICAL ANALYSIS; SURVIVAL RATE; VIRAL GENE DELIVERY SYSTEM; VIRUS ADSORPTION; VIRUS INFECTION; VIRUS ISOLATION;

ADSORPTION; ANTIBODIES, MONOCLONAL; CHOLESTASIS; FIBROSIS; GENE THERAPY; HEMOGLOBINS; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATOCYTES; HUMANS; LIVER; LIVER TRANSPLANTATION; RECOMBINANT PROTEINS;

EID: 34548097603     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Eisenbach C, Sauer P, Mehrabi A, Stremmel W, Encke J. Prevention of hepatitis B virus recurrence after liver transplantation. Clin Transplant 2006;20:111-116.
2. Terrault NA, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996;24:1327-1333.
3. Lu SC, Yan LN, Li B, Wen TF, Zhao JC, Cheng NS, et al. Lamivudine prophylaxis of liver allograft HBV reinfection in HBV related cirrhotic patients after liver transplantation. Hepatobiliary Pancreat Dis Int 2004;3:26-32.
4. Schiff E, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007;13:349-360.
5. Maeda F, Takekoshi M, Nagatsuka Y, Aotsuka S, Tsukahara M, Ohshima A, et al. Production and characterization of recombinant human anti-HBs Fab antibodies. J Virol Methods 2005;127:141-147.
6. Wong SN, Chu CJ, Wai CT, Howell T, Moore C, Fontana RJ, et al. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl 2007;13:374-381.
7. Ning D, Junjian X, Qing Z, Sheng X, Wenyin C, Guirong R, et al. Production of recombinant humanized anti-HBsAg Fab fragment from Pichia pastoris by frmentation. J Biochem Mol Biol 2005;38:294-299.
8. Tang L, Zeng ZG, Pan T, Yuan J, Chen BC, Chen ZH, et al. Expression of recombination human anti-HBsAg Fab in murine liver. Shijie Huaren Xiaohua Zazhi 2006;14:1554-1560.
9. LeCluyse EL, Alexandre E, Hamilton GA, Viollon-Abadie C, Coon DJ, Jolley S, et al. Isolation and culture of primary human hepatocytes. Methods Mol Biol 2004;290:207-229.
10. Neurath AR, Kent SB, Strick N, Parker K. Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell 1986;46:429-436.
11. Glebe D, Aliakbari M, Krass P, Knoop EV, Valerius KP, Gerlich WH. Pre-sl antigen-dependent infection of Tupaia hepatocyte cultures with human hepatitis B virus. J Virol 2003;77:9511-9521.
12. Lo CM, Fung JT, Lau GK, Liu CL, Cheung ST, Lai CL, et al. Development of antibody to hepatitis B surface antigen after liver transplantation for chronic hepatitis B. Hepatology 2003;37:36-43.
13. Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 2000;32: 1189-1195.
14. Protzer-Knolle U, Naumann U, Bartenschlager R, Berg T, Hopf U, Meyer zum Buschenfelde KH, et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998;27:254-263.
15. Trautwein C. Mechanisms of hepatitis B virus graft reinfection and graft damage after liver transplantation. J Hepatol 2004;41:362-369.
16. Boder ET, Wittrup KD. Yeast surface display for directed evolution of protein expression, affinity, land stability. Methods Enzymol 2000;328:430-444.
17. Becker W, Goldenberg DM, Wolf F. The use of monoclonal antibodies and antibody fragments in the imaging of infectious lesions. Semin Nucl Med 1994;24:142-153.
18. Zheng DY, Luo RC, Cai HB. Conditions for large-scale production of genetically engineered E. coli bearing humanized anti-HBsAg Fab. Di Yi Jun Yi Da Xue Xue Bao 2004;24:517-520.